These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 33887878)

  • 1. Potential of the tumor‑derived extracellular vesicles carrying the miR‑125b‑5p target TNFAIP3 in reducing the sensitivity of diffuse large B cell lymphoma to rituximab.
    Zhang L; Zhou S; Zhou T; Li X; Tang J
    Int J Oncol; 2021 Jun; 58(6):. PubMed ID: 33887878
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Ning F; Wang H; Liang Z; Lan J
    Discov Med; 2024 Aug; 36(187):1627-1640. PubMed ID: 39190378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the "Smart" exosome nanoparticle therapy.
    Wu X; Ban C; Deng W; Bao X; Tang N; Wu Y; Deng Z; Xiong J; Zhao Q
    Mol Cancer; 2024 Jul; 23(1):144. PubMed ID: 39004737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1/CD20.
    Jiang D; Mo Q; Sun X; Wang X; Dong M; Zhang G; Chen F; Zhao Q
    Cancer Sci; 2021 Sep; 112(9):3585-3597. PubMed ID: 34252986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
    Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
    Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA CHROMR/miR-27b-3p/MET axis promotes the proliferation, invasion, and contributes to rituximab resistance in diffuse large B-cell lymphoma.
    Liu C; Zhao X; Wang Z; Zhang C; Zheng W; Zhu X; Zhang D; Gong T; Zhao H; Li F; Guan T; Guo X; Zhang H; Yu B
    J Biol Chem; 2024 Mar; 300(3):105762. PubMed ID: 38367665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
    Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
    EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. microRNA‑196a‑3p inhibits cell proliferation and promotes cell apoptosis by targeting ADP ribosylation factor 4 in diffuse large B‑cell lymphoma.
    Fu J; Lou X; Wan S; Zhao X; Chen Z; Zhu M; Guo L; Wu D; Wang S
    Oncol Rep; 2021 Feb; 45(2):764-775. PubMed ID: 33416178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.
    Jin J; Wang L; Tao Z; Zhang J; Lv F; Cao J; Hu X
    Mol Med Rep; 2020 May; 21(5):2209-2219. PubMed ID: 32186759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach.
    de Jong MRW; Visser L; Huls G; Diepstra A; van Vugt M; Ammatuna E; van Rijn RS; Vellenga E; van den Berg A; Fehrmann RSN; van Meerten T
    PLoS One; 2018; 13(2):e0193098. PubMed ID: 29489886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
    Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
    Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
    BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD20 expression, TrkB activation and functional activity of diffuse large B cell lymphoma-derived small extracellular vesicles.
    Aitamer M; Akil H; Vignoles C; Branchaud M; Abraham J; Gachard N; Feuillard J; Jauberteau MO; Shirvani H; Troutaud D; Bentayeb H
    Br J Cancer; 2021 Dec; 125(12):1687-1698. PubMed ID: 34743199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. slan
    Vermi W; Micheletti A; Finotti G; Tecchio C; Calzetti F; Costa S; Bugatti M; Calza S; Agostinelli C; Pileri S; Balzarini P; Tucci A; Rossi G; Furlani L; Todeschini G; Zamò A; Facchetti F; Lorenzi L; Lonardi S; Cassatella MA
    Cancer Res; 2018 Jul; 78(13):3544-3559. PubMed ID: 29748373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffuse large B cell lymphoma-derived extracellular vesicles educate macrophages to promote tumours progression by increasing PGC-1β.
    Liu W; Zhu M; Wang H; Wang W; Lu Y
    Scand J Immunol; 2020 Feb; 91(2):e12841. PubMed ID: 31833575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reverse effect of Semaphorin-3F on rituximab resistance in diffuse large B-cell lymphoma via the Hippo pathway.
    Li Q; Ma N; Li X; Yang C; Zhang W; Xiong J; Zhu L; Li J; Wen Q; Gao L; Yang C; Rao L; Gao L; Zhang X; Rao J
    Chin Med J (Engl); 2023 Jun; 136(12):1448-1458. PubMed ID: 37114652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma.
    Elbaz O; Shaat RM; Abd El Ghaffar HA; Shamaa S; Abdel-Masseih HM; Anber N; Mortada MI
    Asian Pac J Cancer Prev; 2023 Jul; 24(7):2485-2491. PubMed ID: 37505783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
    Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ
    Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in proteomics in diffuse large B‑cell lymphoma (Review).
    Guo Z; Wang C; Shi X; Wang Z; Tao J; Ma J; Bi L
    Oncol Rep; 2024 Jun; 51(6):. PubMed ID: 38757403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.